Latest News

Shanghai China, July 8, 2020 – Asieris Pharmaceuticals (Asieris), a China-based biotech company with global aspirations to discover, develop and commercialize innovative drugs for the treatment of genitourinary tumors and related diseases, announced today it has received Clinical Trial Approval (CTA) from China’s National Medical Products Administration (NMPA) for the global, multi-centered Phase III clinical trial of its photodynamic drug-device combination product, APL-1702 (Cevira^®), which is being developed for the non-surgical treatment of high-grade cervical dysplasia (HSIL).

Oslo, Norway, 1 July 2020: Photocure ASA (OSE:PHO), today announced the appointment of Susanne Strauss as Vice President and General Manager of Europe, effective 1 July 2020.

FINANCIAL YEAR 2020

18.08.2020 - Half-yearly Report

12.11.2020 - Quarterly Report - Q3

Oslo, Norway, 26 June 2020: Reference is made to the previous stock exchange notices where Photocure ASA ("Photocure" or the "Company") announced the allocation of 2,500,000 shares at a subscription price of NOK 76 per share, raising gross proceeds of approx. NOK 190,000,000 in a private placement (the "Private Placement"). The shares will be listed on the Oslo Stock Exchange and are tradeable from today, 26 June 2020.

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

Oslo, Norway, 11 June 2020: Reference is made to the OSE notification 27 April 2020 from Photocure ASA (Photocure, PHO: OSE) regarding the return of Hexvix^® sales, marketing and distribution rights in Europe and other markets currently controlled by Ipsen Pharma SAS (Ipsen). Photocure and Ipsen have today entered into a final agreement.

Oslo, Norway, 10 June 2020: Photocure ASA (OSE: PHO), held its annual general meeting on 10 June 2020 at 17:00 hours (CET).

Oslo, Norway, 10 June 2020: Photocure ASA (OSE:PHO) today announces the company’s first sustainability report, which will be presented at the Annual General Meeting (AGM) at 17:00 CET. The AGM will be live streamed and Dan Schneider, President & Chief Executive Officer, will provide a general company update.

Oslo, Norway, 8 June 2020: Reference is made to the stock exchange announcement by Photocure ASA ("Photocure") published 2 May 2019 regarding a share capital increase as part of the employee long-term incentive program for restricted shares in the company.

Oslo, Norway, June 5, 2020 - Photocure ASA (OSE: PHO) will be presenting at the annual ABG Sundal Collier Virtual Oncology Seminar on June 10. This event features Norwegian companies in the oncology space.

Oslo, Norway, 27 May 2020: Reference is made to the stock exchange announcement by Photocure ASA ("Photocure") published 25 May 2020 regarding a share capital increase following the exercise of employee share options.

Oslo, Norway, 25 May 2020.

Participants in the Photocure ASA’s share option program have on 25 May 2020 exercised a total of 123,750 options. The share options are exercised at an average strike price of NOK 40.81. Each option gives a right to receive one share in the company. The share options are described in note 7 in Photocure’s annual financial statements of 2019.

Oslo, Norway, 20 May 2020: Photocure ASA (OSE: PHO), calls for the annual general meeting (webcast) of PHO to be held at Advokatfirmaet Selmer AS' premises in Tjuvholmen allé 1, 0252 Oslo, Norway on 10 June 2020 at 17:00 hours (CET).

OSLO, Norway, 15 May 2020 -- Photocure ASA (OSE: PHO) today announced key data was published by the 2020 American Urological Association (AUA) Annual Virtual Meeting. Three abstracts featured Blue Light Cystoscopy (BLC™) with Cysview, and on June 27, 2020 BLC with Cysview will be included in a virtual session of the AUA program: “Surgical Techniques: Tips & Tricks Oncology: Bladder Cancer Blue Light” with Dr. Anne Schuckman.

Oslo, Norway, 7 May 2020: Photocure ASA (OSE:PHO) announced the first quarter 2020 results in the trading update 27 April 2020, stating a revenue growth of 33% for the U.S. market in the first quarter of 2020, contributing to Hexvix^®/Cysview^® revenues of NOK 54.4 million (Q1 2019: NOK 51.2 million) and an EBITDA of NOK -4.8 million (NOK -1.5 million). The company has agreed terms with Ipsen Pharma SAS (Ipsen) for the return of Hexvix sales, marketing and distribution rights from the fourth quarter of 2020 and sees significant growth opportunities in Europe. The agreement is expected to be EBITDA accretive from full-year 2021 and beyond.

Oslo, Norway, 30 April 2020: Photocure ASA (Photocure, PHO: OSE) will announce the first quarter 2020 financial results on Thursday 7 May 2020 at 07:00 CET and invites investors, analysts and the media to a presentation at 15:00 CET the same day.

Oslo, Norway, 28 April 2020: Board member Einar Antonsen has notified Photocure ASA that he resigns as a member of the board of directors of Photocure with immediate effect.

Oslo, Norway, 28 April 2020: Reference is made to the previous stock exchange notices where Photocure ASA ("Photocure" or the "Company") announced the allocation of 2,179,638 shares at a subscription price of NOK 65.50 per share, raising gross proceeds of approximately NOK 143 million in a private placement (the "Private Placement") .